XW

XWELL, Inc.

XWELHealthcareNASDAQ

Diagnostics & Research

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$29.2M
-13.8% YoY
Net Income
-$17.0M
-0.8% YoY
EBITDA
-$14.2M
-1.3% YoY
Free Cash Flow
-$8.2M

Scan Results

Daily timeframe
DateIndicatorDetails
Oct 16▼ MACD Negative CrossoverHistogram -0.0081, negative momentum
Oct 15▼ MACD Negative CrossoverHistogram -0.0068, negative momentum
About XWELL, Inc.

XWELL, Inc. engages in the provision of health and wellness services to travelers in the United States and internationally. The company carries a $6.8M market cap, placing it firmly in the micro-cap category. It operates in three segments: XpresSpa, XpresTest, and Naples Wax Center.

Where XWEL stands vs its 150-day and 200-day moving averages

As of the October 16, 2026 close, XWEL finished 32.43% below its 150-day moving average ($1.11) and 24.24% below its 200-day moving average ($0.99). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is XWEL overbought or oversold?

At the October 16, 2026 close, XWEL's RSI(14) was 35.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$6.8M
Fwd P/E-0.26
EPS$-5.24
Beta0.94
52W Change-32.0%
Dividend Yield0.00%
ROE-361.4%
Analysis

With $11.8M in cash and $7.3M in debt, XWEL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$8.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -361.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $55.9M (2022) to $29.2M (2025), a 48% decline worth watching.

The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing XWEL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms